FI67844C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3,5-diamino-6-(substituerad fenyl)-1,2,4-triazinderivat - Google Patents

Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3,5-diamino-6-(substituerad fenyl)-1,2,4-triazinderivat Download PDF

Info

Publication number
FI67844C
FI67844C FI801758A FI801758A FI67844C FI 67844 C FI67844 C FI 67844C FI 801758 A FI801758 A FI 801758A FI 801758 A FI801758 A FI 801758A FI 67844 C FI67844 C FI 67844C
Authority
FI
Finland
Prior art keywords
diamino
hydrogen
triazine
compound
methyl
Prior art date
Application number
FI801758A
Other languages
English (en)
Finnish (fi)
Other versions
FI801758A7 (fi
FI67844B (fi
Inventor
Martin George Baxter
Albert Reginald Elphick
Alistair Ainslie Miller
David Alan Sawyer
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10505597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI67844(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of FI801758A7 publication Critical patent/FI801758A7/fi
Priority to FI840888A priority Critical patent/FI73203C/fi
Application granted granted Critical
Publication of FI67844B publication Critical patent/FI67844B/fi
Publication of FI67844C publication Critical patent/FI67844C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/15—Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI801758A 1979-06-01 1980-05-30 Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3,5-diamino-6-(substituerad fenyl)-1,2,4-triazinderivat FI67844C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI840888A FI73203C (fi) 1979-06-01 1984-03-06 Mellanprodukt foer anvaendning vid framstaellning av terapeutiskt anvaendbara 3,5-diamino-6-fenyl-1,2,4- triazinderivat och foerfarande foer dess framstaellning.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7919257 1979-06-01
GB7919257 1979-06-01

Publications (3)

Publication Number Publication Date
FI801758A7 FI801758A7 (fi) 1980-12-02
FI67844B FI67844B (fi) 1985-02-28
FI67844C true FI67844C (fi) 1985-06-10

Family

ID=10505597

Family Applications (1)

Application Number Title Priority Date Filing Date
FI801758A FI67844C (fi) 1979-06-01 1980-05-30 Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3,5-diamino-6-(substituerad fenyl)-1,2,4-triazinderivat

Country Status (30)

Country Link
US (2) US4486354A (enExample)
EP (2) EP0059987B1 (enExample)
JP (2) JPS5625169A (enExample)
AR (1) AR227521A1 (enExample)
AT (1) AT370097B (enExample)
AU (2) AU530999B2 (enExample)
BG (1) BG60427B2 (enExample)
CA (1) CA1112643A (enExample)
CS (1) CS234018B2 (enExample)
CZ (1) CZ384891A3 (enExample)
DD (1) DD151309A5 (enExample)
DK (1) DK153787C (enExample)
ES (1) ES8104993A1 (enExample)
FI (1) FI67844C (enExample)
GE (1) GEP19960470B (enExample)
GR (1) GR68380B (enExample)
HU (1) HU182086B (enExample)
IE (1) IE49823B1 (enExample)
IL (1) IL60201A (enExample)
IT (1) IT1147087B (enExample)
MX (1) MX9202962A (enExample)
MY (1) MY8500062A (enExample)
NL (1) NL950007I2 (enExample)
NZ (1) NZ193890A (enExample)
PL (1) PL124029B1 (enExample)
SU (1) SU1055331A3 (enExample)
UA (1) UA5576A1 (enExample)
YU (1) YU145680A (enExample)
ZA (1) ZA803250B (enExample)
ZW (1) ZW12980A1 (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311701A (en) * 1979-08-16 1982-01-19 Barbara Roth Treatment of convulsions with triazines
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
DE3600891A1 (de) * 1986-01-15 1987-07-16 Bayer Ag 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4972496A (en) * 1986-07-25 1990-11-20 Grid Systems Corporation Handwritten keyboardless entry computer system
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
ES2089498T3 (es) * 1991-01-30 1996-10-01 Wellcome Found Comprimidos dispersables en agua.
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
DE69307705T2 (de) * 1992-06-12 1997-05-22 Wellcome Found Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
AU4311596A (en) * 1994-12-30 1996-07-24 Wellcome Foundation Limited, The Process for the preparation of lamotrigine
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6202491B1 (en) 1997-07-22 2001-03-20 Skf Condition Monitoring, Inc. Digital vibration coupling stud
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
PL348865A1 (en) * 1998-12-14 2002-06-17 Torrent Pharmaceuticals Ltd An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
IN183150B (enExample) * 1998-12-14 1999-09-25 Torrent Pharmaceuticals Ltd
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
CA2370030C (en) * 1999-04-09 2007-08-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
GB9907965D0 (en) 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
WO2001049669A1 (en) * 2000-01-03 2001-07-12 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
IL134730A (en) * 2000-02-25 2003-10-31 Chemagis Ltd Process for preparing substituted benzoyl cyanide amidinohydrazones
JP2004514700A (ja) 2000-11-30 2004-05-20 ファイザー・プロダクツ・インク Ｇａｂａアゴニスト及びアルドース還元酵素阻害剤の組み合わせ
HRP20030420A2 (en) 2000-11-30 2004-08-31 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors
IL157608A0 (en) * 2001-02-27 2004-03-28 Teva Pharma New crystal forms of lamotrigine and processes for their preparations
DE60209152T2 (de) 2001-09-03 2006-08-03 Newron Pharmaceuticals S.P.A. Pharmazeutische zusammensetzung, umfassend gabapentin oder ein analogon davon und ein alpha-aminoamid
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
DE60312670T2 (de) * 2002-04-23 2007-12-06 Teva Pharmaceutical Industries Ltd. Pharmazeutische zusammensetzung enthaltend lamotrigine-partikel mit definierter morphologie
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
WO2004083191A1 (en) * 2003-03-17 2004-09-30 Hetero Drugs Limited Novel crystalline forms of lamotrigine
WO2004085426A1 (en) 2003-03-27 2004-10-07 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
JP2006528676A (ja) 2003-05-16 2006-12-21 ファイザー・プロダクツ・インク 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
BRPI0507190A (pt) * 2004-01-29 2007-06-26 Pfizer Prod Inc combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
RU2391973C2 (ru) * 2004-09-10 2010-06-20 Ньюрон Фармасьютикалс С.П.А. Применение (галобензилокси)бензиламино-пропанамидов для производства лекарственных средств, действующих как селективные модуляторы натриевых и/или кальциевых каналов
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
JP2009508953A (ja) * 2005-09-23 2009-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヘキサヒドロ−シクロヘプタピラゾール系カンナビノイドモジュレーター
DK1931335T3 (da) * 2005-09-23 2010-06-07 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl-pyrazol-cannabinoid-modulatorer
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
AU2006292051B2 (en) 2005-09-23 2012-11-15 Janssen Pharmaceutica, N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
WO2007092456A2 (en) * 2006-02-03 2007-08-16 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
WO2007095513A1 (en) * 2006-02-14 2007-08-23 Janssen Pharmaceutica, Nv Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007122638A2 (en) * 2006-04-26 2007-11-01 Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd. An improved process for preparation of lamotrigine intermediates
WO2007138075A1 (en) * 2006-05-31 2007-12-06 Calaire Chimie Sas Method for preparing lamotrigine and its intermediate 2,3-dichlorobenzoyl chloride
GB0613836D0 (en) * 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
US20120142919A1 (en) 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CN101506178A (zh) * 2006-08-14 2009-08-12 隆沙有限公司 制备拉莫三嗪的方法
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2010248943B2 (en) 2009-05-13 2015-05-21 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
EP2263657B1 (en) 2009-05-20 2013-07-17 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471729A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
US20110052686A1 (en) 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013183985A1 (en) 2012-06-05 2013-12-12 Erasmus University Medical Center Rotterdam Method of treating cognitive impairment and compounds for use therein
US10189859B2 (en) * 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
WO2016198878A1 (en) 2015-06-12 2016-12-15 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
WO2018109152A1 (en) 2016-12-16 2018-06-21 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
GB2641294A (en) 2024-05-24 2025-11-26 Novumgen Ltd An orodispersible tablet of Lamotrigine and its process of preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759014A (en) * 1952-02-26 1956-10-10 Wellcome Found Improvements in triazines and their manufacture
AT190941B (de) * 1954-09-22 1957-07-25 Chemie Linz Ag Verfahren zur Herstellung neuer Guanylhydrazone
US2952677A (en) * 1956-10-01 1960-09-13 Ici Ltd Aminoguanadine compounds
BE663481A (enExample) * 1964-05-05
GB1204631A (en) * 1967-10-12 1970-09-09 Shell Int Research Pharmacologically active benzylideneamino guanidines and their use
GB1223492A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
US4311701A (en) * 1979-08-16 1982-01-19 Barbara Roth Treatment of convulsions with triazines

Also Published As

Publication number Publication date
US4602017A (en) 1986-07-22
CZ384891A3 (en) 1993-10-13
DK153787C (da) 1989-01-16
MX9202962A (es) 1992-07-01
EP0021121A1 (en) 1981-01-07
EP0059987B1 (en) 1985-08-14
AU566870B2 (en) 1987-11-05
JPS6133163A (ja) 1986-02-17
AR227521A1 (es) 1982-11-15
BG60427B2 (bg) 1995-03-31
ES491998A0 (es) 1981-05-16
IL60201A (en) 1984-05-31
GEP19960470B (en) 1996-08-29
ES8104993A1 (es) 1981-05-16
DK153787B (da) 1988-09-05
AU530999B2 (en) 1983-08-04
AT370097B (de) 1983-02-25
US4486354A (en) 1984-12-04
EP0059987A1 (en) 1982-09-15
DD151309A5 (de) 1981-10-14
NZ193890A (en) 1984-07-06
UA5576A1 (uk) 1994-12-28
FI801758A7 (fi) 1980-12-02
IE801126L (en) 1980-12-01
PL124029B1 (en) 1982-12-31
NL950007I2 (nl) 1997-02-03
IL60201A0 (en) 1980-07-31
JPH0144179B2 (enExample) 1989-09-26
ATA289680A (de) 1982-07-15
HU182086B (en) 1983-12-28
CA1112643A (en) 1981-11-17
IT1147087B (it) 1986-11-19
AU5890680A (en) 1980-12-04
JPS5625169A (en) 1981-03-10
EP0021121B1 (en) 1983-05-11
ZW12980A1 (en) 1982-01-06
GR68380B (enExample) 1981-12-28
JPH0144706B2 (enExample) 1989-09-29
IE49823B1 (en) 1985-12-25
ZA803250B (en) 1982-01-27
FI67844B (fi) 1985-02-28
MY8500062A (en) 1985-12-31
NL950007I1 (nl) 1995-06-16
SU1055331A3 (ru) 1983-11-15
DK233880A (da) 1980-12-02
PL224633A1 (enExample) 1981-02-13
YU145680A (en) 1983-02-28
IT8048848A0 (it) 1980-05-30
CS234018B2 (en) 1985-03-14

Similar Documents

Publication Publication Date Title
FI67844C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3,5-diamino-6-(substituerad fenyl)-1,2,4-triazinderivat
US7960427B2 (en) 5-hydroxyindole-3-carboxylate derivatives and uses thereof
US4585771A (en) Antiinflammatory imidazole derivatives
NZ220361A (en) Distamycin a analogs and pharmaceutical compositions
JPS62161763A (ja) ７‐アミノ‐１シクロプロピル‐４‐オキソ‐１，４‐ジヒドロ‐ナフチリジンまたは‐キノリン‐３‐カルボン酸類またはその塩及びそれらの製造法
US6165980A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
EP1064281B1 (en) Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor agents
EP0142306A2 (en) Triazine compounds having cardiovascular activity
SK3702001A3 (en) 2-phenylpyran-4-one derivatives
NZ203221A (en) 1-(benz-amino(benzylideneamino or phenacyl)guanidine derivatives
CS272226B2 (en) Method of new lensofuran-2 ylimidazol derivatives production
IL98008A (en) Amidino-, carbamoyl or thiocarbamoyl-1-indanone-2'-amidinohydrazone derivatives and analogues thereof that inhibit s-adenoylmethionine decarboxylase
AU2002323774B2 (en) New compounds for treating impotence
US4742077A (en) Bicyclic allylether derivatives, processes for their production and their use
US3829422A (en) 1,4-substituted-pyrimidin-2(1h)-ones
EP2543661B1 (en) Guanylhydrazone compounds, compositions, methods of making and using
HUT60492A (en) Process for producing n-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepta/b/-indole compounds
CA1133938A (en) Substituted aromatic compounds
JPS61271280A (ja) 新規アゾ−ル誘導体、その製造方法と用途
US3787410A (en) Carboxyamido substituted-2-alkylthio-5-pyrimidinesulfonamides
US4376122A (en) Novel 3-substituted amino-1-heteroaryl-2-pyrazolines
JPS6026777B2 (ja) 新規オキシムエーテル化合物およびその塩類
US3767650A (en) 3-amino-2-aryl-acroleins
JPS62155272A (ja) 置換４−フルオロ−イソインドリン類、それらの製造方法及び使用並びにそれらの化合物を含有する調合剤
CA1171090A (en) 7-(2,6-dibromo-4-methylphenyl)-2,3-dihydro- imidazo[1,2-a]imidazoles, the acid addition salts thereof, pharmaceutical compositions containing them and processes for the preparation thereof

Legal Events

Date Code Title Description
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L54

Extension date: 20050530

MA Patent expired

Owner name: THE WELLCOME FOUNDATION LIMITED